# Sagimet Biosciences Inc.: overview

SGMT · Nasdaq · CIK 1400118 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sgmt.md) · [Financials](/companies/sgmt/financials.md) · [Filings](/companies/sgmt/filings.md) · [Insiders](/companies/sgmt/insiders.md)

Latest reported revenue: [$0](/filings/0001558370-25-002747.md) for Q4 FY2023, three months to 2023-12-31, from the 10-K filed Mar 12, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001558370-25-002747).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.45)](/filings/0001104659-25-110846.md) | not reported | [(0.56)](/filings/0001104659-26-059006.md) | [(0.32)](/filings/0001193125-26-343441.md) | [(0.40)](/filings/0001104659-25-110846.md) | not reported | [(0.33)](/filings/0001104659-26-059006.md) | [(0.26)](/filings/0001193125-26-343441.md) |
| Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | [2,000](/filings/0001558370-25-002747.md) | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | [(1537.0%)](/filings/0001558370-25-002747.md) | not reported | not reported |
| Net margin | % | not reported | [(1393.8%)](/filings/0001558370-25-002747.md) | not reported | not reported |
| Diluted EPS | $ per share | [(165.20)](/filings/0001558370-24-003812.md) | [(2.66)](/filings/0001558370-25-002747.md) | [(1.45)](/filings/0001104659-26-026140.md) | [(1.58)](/filings/0001104659-26-026140.md) |
| Free cash flow | $k | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sgmt/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $50.8m | 6,575,788 |  | Added +5,775,845 |
| [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $28.0m | 3,626,113 |  | New +3,626,113 |
| [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $23.2m | 3,000,652 |  | Added +1,999,709 |
| [SILVERARC CAPITAL MANAGEMENT, LLC](/funds/1816307.md) | 2026-06-30 | $22.6m | 2,927,698 |  | New +2,927,698 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $19.8m | 2,566,272 |  | Added +1,467,353 |
| [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $19.3m | 2,500,000 |  | New +2,500,000 |
| [Caligan Partners LP](/funds/1727492.md) | 2026-06-30 | $19.3m | 2,500,000 |  | New +2,500,000 |
| [Affinity Asset Advisors, LLC](/funds/1773195.md) | 2026-06-30 | $19.3m | 2,497,864 |  | Added +1,629,844 |
| [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $16.1m | 2,086,715 |  | Added +2,085,934 |
| [GREAT POINT PARTNERS LLC](/funds/1281446.md) | 2026-06-30 | $15.7m | 2,029,933 |  | New +2,029,933 |

## Recent filings

[All 260 filings](/companies/sgmt/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-22 | 11:15 ET | [8-K](/filings/0001193125-26-428314.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-428314 |
| 2026-10-01 | 22:00 ET | [8-K](/filings/0001193125-26-409335.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-409335 |
| 2026-09-30 | 10:09 ET | [8-K](/filings/0001193125-26-408224.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-408224 |
| 2026-08-13 | 11:05 ET | [8-K](/filings/0001193125-26-347854.md) | 8.01 Other events | 0001193125-26-347854 |
| 2026-08-11 | 11:35 ET | [8-K](/filings/0001193125-26-343446.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-343446 |
| 2026-08-11 | 11:30 ET | [10-Q](/filings/0001193125-26-343441.md) | Quarterly report, period 2026-06-30 | 0001193125-26-343441 |
| 2026-07-21 | 01:35 ET | [8-K](/filings/0001193125-26-309334.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-309334 |
| 2026-06-12 | 20:06 ET | [8-K](/filings/0001104659-26-073431.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001104659-26-073431 |
| 2026-06-03 | 20:30 ET | [8-K](/filings/0001104659-26-070126.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-070126 |
| 2026-05-12 | 11:35 ET | [8-K](/filings/0001104659-26-059009.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-059009 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-026140.md), filed Mar 11, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1400118
- Tickers: SGMT
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.